Hosted by Unknown Host · 🇺🇸 US · EN-US · 56 episodes
Established thought leaders with verified media credentials.
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, video capsules, and podcasts at: https://www.impactmedicom.com.
Unknown Host hosts IMPACT Medicom, a science show with 56 episodes published.
Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet need in hematology.
In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap. Our guest Dr. Puckrin is a Hematologist a
In this podcast episode, Dr. Dimitrios Coutsinos describes a video capsule series involving three educational videos of lung resections using minimally invasive video-assisted thoracic surgery (VATS) following neoadjuvan
In this podcast episode, we discuss clinical trial updates in chronic lymphocytic leukemia from the 2025 European Hematology Association annual congress in Milan, Italy and the 18th International Conference on Malignant
(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin
In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our Guest Dr. Michael
In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented a
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest: Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist a
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examine
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new target
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the
In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest: Dr. Lipson is an internationally-recognized skin cancer and immunothe
In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice. Our Guests: D
In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficac
In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This fifth episode of the series was recorded live from ESMO
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
IMPACT Medicom has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
IMPACT Medicom is hosted by Unknown Host. The show is categorised under science and has published 56 episodes.
IMPACT Medicom has published 56 episodes.
IMPACT Medicom regularly covers science. It sits in the science category.
IMPACT Medicom is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
IMPACT Medicom hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of IMPACT Medicom average 22 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates IMPACT Medicom's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 8 days ago.
